



Peña, O. A., Lubin, A., Hockings, C., Rowell, J., Jung, Y., Hoade, Y., Dace, P., Valdivia, L. E., Tuschl, K., Böiers, C., Virgilio, M. C., Richardson, S., & Payne, E. M. (2021). TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signaling. *Blood Advances*, 5(20), 4112-4124. <https://doi.org/10.1182/bloodadvances.2020003055>

Publisher's PDF, also known as Version of record

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1182/bloodadvances.2020003055](https://doi.org/10.1182/bloodadvances.2020003055)

[Link to publication record on the Bristol Research Portal](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via American Society for Hematology at <https://doi.org/10.1182/bloodadvances.2020003055>. Please refer to any applicable terms of use of the publisher.

University of Bristol – Bristol Research Portal

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/brp-terms/>

TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signaling

Oscar A. Peña,^{1,*} Alexandra Lubin,^{1,*} Catherine Hockings,^{1,†} Jasmine Rowell,^{1,†} Youngrock Jung,¹ Yvette Hoade,¹ Phoebe Dace,¹ Leonardo E. Valdivia,^{2,3} Karin Tuschl,^{2,4} Charlotta Böiers,⁵ Maria C. Virgilio,¹ Simon Richardson,⁵ and Elspeth M. Payne^{1,6}

¹Research Department of Haematology, Cancer Institute; ²Department of Cell and Developmental Biology, University College London, London, United Kingdom; ³Center for Integrative Biology, Universidad Mayor, Santiago, Chile; ⁴Genetics and Genomic Medicine, UCL Institute of Child Health; ⁵Research Department of Cancer Biology, Cancer Institute, University College London, London, United Kingdom; and ⁶Clinical Research Facility, National Institute for Health Research/University College London Hospitals (NIHR/UCLH), National Health Service (NHS) Foundation Trust, London, United Kingdom

Key Points

- Rps14-deficient zebrafish demonstrate features of MDS and impaired stress responses.
- Rps14-induced anemia is rescued on ligation of Tlr7, via paradoxical suppression of inflammatory signalling and enhanced differentiation.

Myelodysplastic syndrome (MDS) is a hematological malignancy characterized by blood cytopenias and predisposition to acute myeloid leukemia (AML). Therapies for MDS are lacking, particularly those that have an impact in the early stages of disease. We developed a model of MDS in zebrafish with knockout of Rps14, the primary mediator of the anemia associated with del(5q) MDS. These mutant animals display dose- and age-dependent abnormalities in hematopoiesis, culminating in bone marrow failure with dysplastic features. We used Rps14 knockdown to undertake an in vivo small-molecule screening, to identify compounds that ameliorate the MDS phenotype, and we identified imiquimod, an agonist of Toll-like receptor-7 (TLR7) and TLR8. Imiquimod alleviates anemia by promoting hematopoietic stem and progenitor cell expansion and erythroid differentiation, the mechanism of which is dependent on TLR7 ligation and Myd88. TLR7 activation in this setting paradoxically promoted an anti-inflammatory gene signature, indicating cross talk via TLR7 between proinflammatory pathways endogenous to Rps14 loss and the NF- κ B pathway. Finally, in highly purified human bone marrow samples from anemic patients, imiquimod led to an increase in erythroid output from myeloerythroid progenitors and common myeloid progenitors. Our findings have both specific implications for the development of targeted therapeutics for del(5q) MDS and wider significance identifying a potential role for TLR7 ligation in modifying anemia.

Introduction

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid malignancies associated with cytopenias and evolution to acute myeloid leukemia (AML). MDS with loss of all or part of the long arm of chromosome 5 (del(5q) MDS) is the most common subtype,¹ and, importantly, 5q loss has been shown to be an initiating event in MDS development in most such cases.^{2,3}

The only curative therapy for patients with MDS remains stem cell transplantation, for which many older patients with MDS are unfit. Thus, there remains an unmet need for novel therapies for del(5q) MDS.

Ribosomal protein of the small subunit, *RPS14* (also now known as uS11⁴), located in the critically deleted region of chromosome 5q, is one of several genes identified as a haploinsufficient tumor suppressor

Submitted 27 July 2020; accepted 30 March 2021; prepublished online on *Blood Advances* First Edition 25 August 2021; published online 21 October 2021. DOI 10.1182/bloodadvances.2020003055.

*O.A.P. and A. L. contributed equally to this study.

†C. H. and J. R. contributed equally to this study and are listed in alphabetical order.

Original data are available by request to the corresponding author.

Sequencing files have been deposited in Gene Expression Omnibus (accession number GSE168727).

The full-text version of this article contains a data supplement.

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

gene in del(5q) MDS.⁵⁻¹⁰ We and others have shown haploinsufficient levels of Rps14 recapitulate features of del(5q) MDS in zebrafish, mice, and primary human cells.^{5,11,12}

Proposed mechanisms for Rps14-mediated hematopoietic defects include p53-dependent apoptosis and increased proinflammatory innate-immune signaling via Toll-like receptor-4 (TLR4), resulting from an increase in translation of the cognate ligands S100A8 and S100A9.¹¹ In addition, activation of TLR-MyD88-NF- κ B signaling in del(5q) MDS results from haploinsufficiency of other genes and microRNAs contained within the 5q critically deleted region.^{7,9} However, signaling through TLR4 is also necessary for the generation of hematopoietic stem and progenitor cells (HSPCs) in both steady-state and stressed hematopoiesis.¹³⁻¹⁵ This finding indicates that homeostatic regulation of inflammatory signaling through TLR pathways is critical to maintaining normal hematopoiesis.

We created a novel zebrafish model of del(5q) MDS, using transcription activator–like effector nucleases (TALENs) to mutate *rps14*. We used Rps14-deficient zebrafish to identify small molecules that alleviate anemia in this model and identified the TLR7/8 agonist imiquimod. This effect was dependent on TLR7 and resulted in improved hemoglobinization and an increase in HSPCs. Importantly, imiquimod led to an increase in erythroid output in both fish and primary human cells from anemic patients, an effect not restricted to, but enhanced by, the haploinsufficiency of Rps14. Analysis of Rps14-deficient HSPCs showed upregulation of negative regulators of canonical WNT signaling, which was reversed after imiquimod exposure. Furthermore, there was paradoxical downregulation of inflammatory signaling and NF- κ B target genes in Rps14^{+/-} embryos exposed to imiquimod, that was dependent on Myd88. These data suggest cross talk between the endogenous proinflammatory effects of Rps14 haploinsufficiency, and TLR7 activation led to attenuation of anemia in our model.

Methods

Zebrafish husbandry

Zebrafish (*Danio rerio*) AB, AB/TL, and transgenic strains *Tg(gata1:DsRed)*, *Tg(itga2b:GFP)*, and *Tg(NF κ B:GFP)*^{sh235} were maintained according to standard procedures and UK Home Office guidelines.¹⁶⁻¹⁹ The embryos were staged according to Kimmel et al²⁰ and expressed in postfertilization hours (hpf) or days (dpf).

Generation of a zebrafish *rps14* mutant line

TALENs targeting exon 2 of the zebrafish *rps14* gene were made by using FLASH.²¹

Morpholinos

Morpholinos (MOs) targeting the 5'UTR/ATG codon (*gata1*) or splice donor sites (*rps14*, *myd88*) or Gene Tools standard control were injected into 1- to 2-cell-stage embryos at doses previously described.^{12,22,23}

Immunohistochemistry

α -Dianisidine staining of hemoglobin and Sudan black (SB) staining to visualize granulocytes were performed as previously described.^{24,25} SB⁺ cells were quantified from the distal end of the yolk extension to the tail tip in the caudal hematopoietic tissue (CHT; fetal liver equivalent in zebrafish).

Induction of stress

Hemolytic stress was induced by exposure of the embryos to phenylhydrazine (PHZ).²⁶ They were incubated in 1 μ g/mL PHZ from 24 to 48 hpf and then washed. Cold stress was induced after gastrulation by placing 6 somite stage embryos at 22°C.

Microscopy

Microscopy was performed with a Leica M205 FA stereomicroscope equipped with a Leica DFC310 FX camera and LAS 4.0 software. All images were processed with Fiji version 2.0.0-rc-43/1.51f or Photoshop CS6.

Statistical analysis

Data are presented as means \pm standard deviation. Analysis was performed with Prism (GraphPad Software, La Jolla CA). Specific statistical tests are shown in the figure legends.

Zebrafish analysis by flow cytometry

Individual embryos and adult zebrafish kidneys were analyzed by flow cytometry, as described previously.¹²

Cell sample preparation and imaging

The cells (1×10^5) were centrifuged onto slides, fixed with methanol, and stained with May-Grunwald-Giemsa stain. Images were taken with the Nanozoomer 2.0 RS (Hamamatsu).

Western blot analysis

Protein lysates were obtained from pooling 6-dpf genotyped embryos. Blots were probed with phospho-eIF2 α (Ser51) (119A11) rabbit mAb (3597; Cell Signaling) and total eIF2 α (ab26197; Abcam).

Results

Rps14 loss results in dose-dependent hematopoietic abnormalities

We have shown that knockdown of Rps14 using MOs results in anemia that models the erythroid defect of del(5q) MDS.¹² We used TALENs to generate a stable Rps14 mutant zebrafish with an early frameshift mutation (*rps14*^{EBfs}; supplemental Figure 1). Using whole-mount immunofluorescence, we demonstrated loss of Rps14 protein in an allelic dose-dependent manner, indicating that Rps14^{EBfs/+} animals have haploinsufficient protein levels that model those in del(5q) MDS (supplemental Figure 2). Rps14^{EBfs/EBfs} embryos, herein referred to as Rps14^{-/-}, showed profound developmental anomalies that were lethal by 5 dpf. α -Dianisidine staining at 4 dpf showed that Rps14^{-/-} embryos have markedly reduced hemoglobinization (Figure 1C) compared with that of Rps14^{+/+} embryos (Figure 1A). However, developmental morphology and hemoglobinization in the Rps14^{+/-} embryos was indistinguishable from that of their Rps14^{+/+} siblings (Figure 1A-B). To quantify erythroid cells, we used Rps14^{EBfs} carrying *Tg(gata1:dsRed)*. Importantly, flow cytometry of the embryos demonstrated a decrease in the number of dsRed-expressing erythroid cells at 3 dpf (Figure 1D; supplemental Figure 3A). This finding indicates that the Rps14^{+/-} embryos had anemia associated with a reduced number of red cells, yet maintained adequate hemoglobinization.

We next determined the impact of Rps14 loss on definitive myelopoiesis. Using SB to stain granulocytes at 4 dpf, we identified a




Figure 1. Rps14 stable mutants show dose-dependent effects on hematopoiesis in embryos. (A-C) Assessment of hemoglobinized cells with *o*-dianisidine staining. Ventral views of the head in 4-dpf embryos. Rps14^{-/-} zebrafish showed profound loss of hemoglobinized cells (C) and developmental anomalies. Rps14^{+/-} were indistinguishable from their WT siblings by microscopy (A-B). (D) Number of erythroid cells by flow cytometry of individual *Tg(gata1:dsRed)*;Rps14^{+/-} embryos at 3 dpf. There was an allelic dose-dependent effect on the dsRed-expressing number of cells. (E-G) SB-stained 4-dpf embryos for granulocytes. (H) Quantification of SB⁺ cells. (K) Region of CHT depicted in cartoon (adapted from Lizzy Griffiths with permission). SB staining shows an allelic dose-dependent effect of Rps14. (I-J) Lateral views of the CHT of 4dpf Rps14 mutant fish carrying the *itga2b:GFP* transgene, labeling HSPCs that reside in the CHT. (L) Quantitation of stationary GFP^{lo} cells in the CHT. (M-N) Expression of *c-myb* by in situ hybridization in 4-dpf embryos. (O) In contrast to *itga2b-GFP*, *c-myb* expression is increased in the CHT, quantified by median expression intensity in CHT.⁵⁸ (P-Q) Lateral views of 12-month-old adult fish show the decreased size of heterozygotes. The anterior faces left and the dorsal side faces upward. The horizontal line shows the body length excluding the tail. (R) Quantification of hemoglobin concentration. (S) Analysis of cell size. Red blood cells were significantly larger in Rps14^{-/-} mutants compared with siblings. (T-U) Micrographs of blood smears from Rps14^{+/-} and WT siblings; the arrowhead indicates poorly hemoglobinized erythroid cell in Rps14^{+/-}. (V-W) Absolute number of cells per microliter of different cell types in the kidney marrow of 5- and 12-month-old fish, showing progressive differences between heterozygous *rps14* mutants and their WT siblings. Statistical comparison by 1-way ANOVA with Tukey's multiple-comparisons test (D,H) or unpaired Student *t* test. Original magnification x100 for panels T and U.

reduction in SB⁺ granulocytes located within the CHT (Figure 1K) in a dose-dependent manner, with allelic loss of Rps14 (Figure 1 E-H).

We then assessed the effects of Rps14 loss on HSPC in the *Tg(itga2b:GFP)* strain, in which GFP^{lo} cells in the CHT label HSPCs.¹⁸ HSPC quantification in the CHT at 4 dpf of Rps14^{+/-} mutants compared with that in Rps14^{+/+} embryos did not demonstrate a significant difference (Figure 1L; supplemental 3B). HSPCs and extensive autofluorescence were virtually absent in the Rps14^{-/-} embryos and were not assessable. We further recorded the number of HSPCs by using whole-mount in situ hybridization (WISH) of *c-myb* in the CHT at 4 dpf. By contrast to the *Tg(itga2b:GFP^{lo})* cells, *c-myb* expression in the CHT increased in Rps14^{+/-} embryos compared with that in Rps14^{+/+} embryos (Figure 1M-O).

Itga2b-GFP^{lo}-expressing cells are some of the first to arise during definitive hematopoiesis and are restricted to HSPC- and megakaryocytic lineage-committed cells, whereas *c-myb* is expressed in a broader subset of HSPCs, as well as more committed myeloid lineage cells (<http://servers.binf.ku.dk/bloodspot/>).²⁷ Therefore the increase in expression of *c-myb* with normal *itga2b* and reduced mature myeloid cells suggests an increase in myeloid-lineage-restricted progenitor cells in Rps14^{+/-} embryos, with a concomitant block in differentiation.

Rps14^{+/-} adult mutants have anemia and features of MDS

Rps14^{+/-} adult zebrafish are significantly smaller than Rps14^{+/+} ones (Figure 1P-Q; supplemental Figure 4A-B). Hemoglobin levels




Figure 2. Hemolytic stress augments the hematopoietic phenotype in *Rps14*^{+/-} mutants and is rescued by imiquimod. (A) Hemolytic stress experiment. (B-C) Representative views (ventral) of *rps14*^{+/+} and *rps14*^{+/-} siblings treated as in panel A and stained with α -dianisidine at 6 dpf. *Rps14*^{+/-} mutants demonstrate a clear anemic phenotype, quantified in panel D. (E) Effect of hemolytic stress on HSPCs. Statistical comparisons were performed with Fisher's exact test (D) or ANOVA (E).

showed a lower concentration of hemoglobin in *Rps14*^{+/-} than in *Rps14*^{+/+} zebrafish (Figure 1R). Furthermore, examination of hematopoietic cell morphology from *Rps14*^{+/-} adults showed cells that have defective hemoglobinization (Figure 1T-U; arrowhead), large red cells (Figure 1S), and dyserythropoiesis in the kidney marrow (supplemental Figure 4C-J).

We next used flow cytometric examination of kidney marrow (the site of adult hematopoiesis) to assess the effects of *Rps14* loss on hematopoiesis. At 5 months of age, an increase in eosinophils and lymphocytes was observed in *Rps14*^{+/-} compared with *Rps14*^{+/+} zebrafish by forward and side scatter examination of the cell populations (Figure 1V; supplemental Figure 4K). We observed an increase in *Tg(itga2b:GFP^o)* cells in the progenitor cell fraction (supplemental Figure 4K-L), a feature observed in murine *Rps14* conditional knockouts.^{19,28} By 12 months, the kidney marrow of *Rps14*^{+/-} mutants showed defects in all lineages, indicating features of bone marrow (BM) failure (Figure 1W; supplemental Figure 4M).

Stress markedly exacerbates the hematopoietic defects in *Rps14* heterozygous animals

To refine the effects of *Rps14* haploinsufficiency on hematopoiesis, we exposed *Rps14*^{+/-} embryos to hematopoietic stress.¹¹ First, we used cold stress, incubating embryos at 22°C from 10 hpf for 4 days to the prim-22 stage (supplemental Figure 5A).²⁹ *Rps14*^{+/-} embryos were significantly more anemic after cold stress than their *Rps14*^{+/+} siblings, with no clear difference in the developmental stage (supplemental Figure 5B-D). To determine the effects of stress specifically on definitive hematopoietic cells, we used hemolytic stress induced by incubating embryos in PHZ for 24 hours (24-48 hpf) and assessed the recovery of hematopoiesis

(Figure 2A).³⁰ Embryos exposed to PHZ showed loss of hemoglobinized erythroid cells by apoptosis (supplemental Figure 6). At 6 dpf, wild-type (WT) animals had completely recovered, with α -dianisidine staining showing normal hemoglobinization, whereas *Rps14*^{+/-} siblings remained markedly anemic (Figure 2B-C, quantified in Figure 2D). We further assessed the effect of hemolytic stress on HSPCs using the *Tg(itga2b:GFP;rps14*^{+/-}) strain. As mentioned previously, *Rps14*^{+/-} embryos showed no difference in the number of *Tg(itga2b:GFP)* HSPCs in the absence of PHZ. PHZ stress resulted in an increase in HSPCs compared with nonstressed animals in WT; however, *Rps14*^{+/-} larvae did not elicit this response, leading to a significant decrease in HSPCs compared with stressed WT siblings (Figure 2E).

Small-molecule screenings identify imiquimod as a modifier of anemia in *Rps14*-deficient embryos

To use our system to assess for potential novel therapeutic agents in del(5q) MDS, we developed a small-molecule screen for modifiers of anemia (Figure 3A). We used MO knockdown of *Rps14*, as the morphant phenotype is comparable to mutants, to obtain an increased number of molecules to be tested.¹² We screened the Spectrum collection for compounds that could alleviate the characteristic morphological defects and/or anemia resulting from *Rps14* MO injection. Treatment of *Rps14* morphants with the TLR7/8 pathway agonist imiquimod strikingly rescued the anemia phenotype of the *Rps14* morphants (Figure 3D) compared with dimethyl sulfoxide (DMSO)-treated negative controls (Figure 3C) to a level similar to that observed in experiments using L-leucine.¹²

We next assessed the improvement in hemoglobinization with DMSO or 5 μ M imiquimod treatment by classifying each larva by




Figure 3. Small-molecule screening for modifiers of anemia in *Rps14* deficiency identifies imiquimod. (A) The screening design. (B-E) *Rps14* 4-dpf morphants and controls treated with DMSO, L-leucine, or imiquimod were stained for hemoglobin with α -dianisidine. Ventral views of the head (top) and lateral (bottom) views, with the anterior facing left and the dorsal facing upward. (F) Semiquantitative analysis of the effects of imiquimod on the severity of hemoglobinization. Imiquimod improved the level of hemoglobinization compared with the DMSO control. Statistical comparisons performed by Fisher's exact test. Original magnification $\times 80$ for panels B-E.

the severity of their anemia. Imiquimod markedly decreased the proportion of larvae with severe anemia (Figure 3F).

Imiquimod rescues stress-induced anemia in *Rps14* heterozygotes

We next assessed the effects of imiquimod on *Rps14*^{+/-} mutants exposed to PHZ. As observed in *Rps14* morphants, imiquimod rescued the anemia observed in stressed *Rps14*^{+/-} mutants (Figure 4A-E). We also observed a dose-dependent effect of imiquimod on the proportion of anemic animals at 6 days (Figure 4F).

Inflammatory signaling through other TLRs has been shown to affect the emergence of HPSCs. To determine at which point during hematopoiesis imiquimod exerted its effect and to assess the effect of TLR7 signaling on HSPC, we used *Tg(itga2b:GFP);rps14*^{+/-} exposed to hemolytic stress and then treated with imiquimod or control. In PHZ-stressed control mutants, GFP^{lo} HSPCs were reduced in *Rps14*^{+/-} compared with *Rps14*^{+/+} embryos. Exposure to imiquimod resulted in an increase in GFP^{lo} cells in both *Rps14*^{+/-} and *Rps14*^{+/+} embryos; however, the effect was more marked in *Rps14*^{+/-} compared with *Rps14*^{+/+} embryos. A 2-way analysis of variance (ANOVA) demonstrated an interaction between the effects of the *Rps14* heterozygosity and imiquimod treatment (Figure 4G).

These findings indicate that imiquimod leads to both improved hemoglobinization and increased HSPCs.

Imiquimod affects erythropoiesis through TLR7 ligation

Imiquimod is an imidazoquinoline, which binds to TLR7 and TLR8 on their dimerization interfaces. This binding is enhanced for TLR7 when single-stranded RNA (its cognate ligand) is bound at a different site.³¹⁻³⁴ To determine whether the hematopoietic effects of imiquimod that we observed were obtained through ligation of TLR7, we used additional small molecules that selectively activate these receptors. Gardiquimod, a specific TLR7 agonist rescued the anemia associated with *Rps14* heterozygosity (Figure 4H-L,N). In contrast, the TLR8-specific agonist motolimod did not rescue the effects (Figure 4J,M). This result indicates that the effects we observed were specific to ligation of TLR7 but not TLR8. To further confirm this notion, we used a Tlr7 crispant knockout (Figure 4O-P). *Rps14*^{+/-} \times *Rps14*^{+/+} clutches were injected with Tlr7 CRISPR guide or control and then exposed to PHZ. TLR7 crispants abrogated the imiquimod-mediated rescue of anemia in *Rps14* heterozygotes (Figure 4Q). These results show that the effects of imiquimod occur specifically through TLR7.

Imiquimod-treated $Rps14^{+/-}$ HSPCs show reversal of WNT signaling and paradoxical downregulation of inflammation and an increase in erythroid differentiation

We sought to define the mechanism by which stress from PHZ led to more marked anemia in $Rps14^{+/-}$ embryos and whether imiquimod alleviated the anemia and reversed the effect. We have observed an increase in phosphorylation of Eif2 α at serine 51 (Eif2 α P) in $Rps19$ morphants,³⁵ which occurs in response to stressors, including free heme, resulting in global translation reduction. We hypothesized that Eif2 α P would also occur in $Rps14^{+/-}$ embryos under PHZ-induced hemolytic stress. At 6 dpf, the Eif2 α P/total ratio was increased in $Rps14^{+/-}$ compared with $Rps14^{+/+}$ embryos ($P = .02$); however, this was not clearly influenced by the presence of PHZ or imiquimod (Figure 5A-B). Therefore, we concluded that $Rps14^{+/-}$ results in Eif2 α P independent of stress, which contributes to defective translation in our model.

To refine further the mechanism by which imiquimod increases HSPCs and mature erythroid cells more potently in $Rps14^{+/-}$ than in WT embryos, we performed RNA sequencing analysis of HSPCs, with or without PHZ stress and treated with imiquimod or vehicle control (supplemental Figure 3C). Systems level analysis of genes confirmed highly significant knockdown of $Rps14$ at the RNA level in HSPCs in heterozygotes across all conditions (Figure 5C).³⁶ Pathway analysis of genes differentially regulated in $Rps14^{+/-}$ compared with $Rps14^{+/+}$ embryos demonstrated enrichment of pathways involving ribosome biogenesis, translation, and p53 and TNF α /NF- κ B signaling (Figure 5D), in keeping with known $Rps14$ -associated pathways in hematopoiesis.^{36,37} The number of differentially regulated genes was relatively few ($n = 35$ -225 between conditions), suggesting that the observed phenotypes most likely arise posttranscriptionally or through non-cell-autonomous effects. To further assess the changes in differentially expressed genes, we undertook Gene Set Enrichment Analysis (GSEA).^{38,39} We observed that negative regulators of canonical WNT signaling were upregulated in PHZ-stressed $Rps14^{+/-}$ HSPCs compared with those of siblings, but were markedly downregulated after exposure to imiquimod (Figure 5E). We also observed reciprocal changes in inflammatory signaling signatures in stressed $Rps14^{+/-}$ compared with siblings, with exposure to imiquimod resulting in a change from pro- to anti-inflammatory signaling (Figure 5F). We validated this observation by using quantitative polymerase chain reaction to identify downstream mediators of TLR-signaling (supplemental Figure 7A). Consistent with our GSEA findings, we showed that the presence of imiquimod reversed the expression level of key NF- κ B proinflammatory target genes in $Rps14$ morphants. To further investigate these findings in $Rps14^{+/-}$ mutants, we used a $Tg(NF\kappa B:GFP)$ reporter line. We

found that PHZ stress led to an increased expression of GFP in $Tg(NF\kappa B:GFP)$ cells at 4 dpf, but this effect was reversed in $Rps14^{+/-}$ compared with $Rps14^{+/+}$ embryos in the presence of imiquimod (Figure 5G). We also assessed levels of interleukin-1 β (IL1 β) by WISH. PHZ exposure resulted in an increased number of embryos with high levels of IL1 β expression, and this effect was again reversed by the presence of imiquimod (Figure 5H). Finally, we used an Myd88 MO to show that loss of Myd88 abrogated the imiquimod-mediated rescue of anemia in $Rps14^{+/-}$ embryos (supplemental Figure 7B), in a way similar to the loss of Tlr7 (Figure 4Q). These data combined show that $Rps14^{+/-}$ mutants have a proinflammatory state through activation of the TLR-MyD88-NF- κ B signaling complex, and treatment of $Rps14^{+/-}$ embryos with imiquimod paradoxically reverses this effect.

Imiquimod enhances erythroid differentiation

Our data suggest that treating $Rps14^{+/-}$ mutants with imiquimod resulted in an increase in HSPCs but also induced an increase in more mature erythroid cells. To assess whether this increase is due to general expansion of the cell pool or a specific effect on erythroid differentiation, we assessed erythroid differentiation in $Rps14^{+/-}$ mutants with and without imiquimod. A GSEA showed that stressed HSPCs have a downregulated erythroid differentiation signature in $Rps14^{+/-}$ compared with that of siblings. Imiquimod reversed this effect, showing a proerythroid differentiation signature (supplemental Figure 8A-B). We used WISH to assess the expression of *gata1* at 3 dpf and showed that, during recovery from PHZ stress, there was an increase in *gata1* expression that was more pronounced in $Rps14^{+/+}$ than in $Rps14^{+/-}$ embryos and that this effect was reduced in the presence of imiquimod (supplemental Figure 8C). To further assess these effects, we ablated all mature erythroid cells using MO knockdown of the master erythropoiesis regulator Gata1 in $Tg(gata1:dsRed)$ transgenic animals.^{19,40} GATA1 has been shown to be central to the mechanism of anemia associated with RPS-14 and other ribosomal proteins.⁴¹⁻⁴⁶ Treatment of Gata1 morphants with imiquimod increased the numbers of circulating and static erythroid cells (supplemental Figure 8E-I; supplemental Movies 1-4), and centrifuging of sorted dsRed cells showed increased numbers of mature erythroid and myeloid cells (supplemental Figure 8J-L). Therefore, our data support that imiquimod not only increases HSPCs but promotes both erythroid and myeloid differentiation on the background of anemia associated with $Rps14$ or Gata1 deficiency.

In vitro hematopoietic colony output is enhanced in anemic human primary cells treated with imiquimod

Our zebrafish studies showed that imiquimod increases HSPCs and can alleviate anemia by enhancing erythroid differentiation in

Figure 4. Imiquimod exerts its effect on $Rps14$ -deficient anemic embryos via on-target activation of TLR7 (A-D) Ventral views of 6-dpf embryos stained with *o*-dianisidine, treated with PHS to induce hemolytic stress or with DMSO (A,C) or with PHZ and imiquimod (B,D). Imiquimod rescued stress-induced anemia. (F) Quantified as the normal/total ratio of embryos across 3 replicates at a concentration of 20 μ M. (E) Effect of imiquimod analyzed across the dose range, analyzed by nonlinear regression. (G) Flow cytometric analysis of *rps14^{Ebis};Tg(itga2b:GFP)* single embryos exposed to hemolytic stress and then treated with DMSO or imiquimod. Imiquimod enhanced the *itga2b:GFP^o* cells, and the effect was most marked in the $Rps14^{+/-}$ embryos, where there was a significant interaction between the drug and genotype. (H-M) Ventral views of 6-dpf embryos stained with *o*-dianisidine, treated to induce hemolytic stress (PHZ) and with DMSO (H,K), gardiquimod (I,L), or motolimod (J,M). Gardiquimod, but not motolimod, rescued the stress-induced anemia in $Rps14^{+/-}$ embryos. (N) The gardiquimod rescue effect analyzed across dose range by nonlinear regression. Tlr7 knockout was validated using Miseq (O) and restriction enzyme digest with *Bpl*I (P), which digested only the WT. (Q) Knockout of Tlr7 abrogated the rescue of anemia by imiquimod. Original magnification x80.




Figure 5.

Rps14- and Gata1-deficient anemia. To determine whether these effects were also observed in human cells, we sought to analyze BM of patients with MDS. Unfortunately, no samples from patients with MDS del(5q) were available for analysis. However, we think that the effect of imiquimod is most likely not limited to patients with ribosomal protein abnormalities, but more to those who have a basal inflammatory state that is common to loss of Rps14 and other MDS subtypes.^{47,48} Therefore, we used patient samples of anemic dysplasia in the BM (supplemental Table 1). HSPC output from patients with anemia was extremely low, with less than 0.02% of plated cells giving rise to any colonies (Figure 6A). This contrasts with the nonanemic control where 8% of plated cells gave rise to colonies (supplemental Figure 9A) and where the overall colony output was enhanced by imiquimod.

In both common myeloid progenitors (CMPs) and megakaryocyte/erythroid progenitors (MEPs) from anemic patients we observed an increase in colony output in the imiquimod-treated cells compared with the controls (Figures 6B-C). This finding reflects an increase in both colony-forming unit-granulocytes, erythrocytes, macrophages, and megakaryocytes (GEMMs) and burst-forming unit-erythroids. In contrast, there was no effect on overall colony output from granulocyte-monocyte progenitors, rather a lineage bias toward more mature myeloid (Granulocyte-Macrophage (GM) and granulocyte (G)) colonies rather than GEMMs (Figure 6D). To further highlight the effects at the MEP and CMP level, Figure 6E-J shows the output from each patient with or without the addition of imiquimod. Although these results did not reach significance, taken together the data indicate that the effects of imiquimod treatment on erythropoiesis may result from effects at the level of both CMPs and MEPs in human cells. Our data also indicate that imiquimod has variable effects at different stages of lineage commitment in both the myeloid and erythroid compartments and that these are not limited to Rps14 deficiency, suggesting that cross talk between mediators of inflammation may occur more widely.

Discussion

In this study, we generated a model of del(5q) MDS, using TALENS to introduce a frameshift mutation in Rps14. Embryos deficient in Rps14 showed dose-dependent defects in the number of mature myeloid cells. Erythropoiesis was similarly reduced; however, the effects on the erythroid lineage as well as HSPCs were much more striking after exposure to stress. These findings suggest that Rps14 haploinsufficiency has significant effects on steady-state hematopoiesis, but that Rps14 also has a specific role in the maintenance of stress-induced hematopoiesis. As PHZ results in stress to the hematopoietic system by hemolysis, we assessed whether the Rps14-specific effects of PHZ is mediated by stress-response pathways

sensitive to free heme via Eif2 α P. Interestingly, although we did not show an effect of PHZ on Eif2 α P, Rps14^{+/-} mutants, regardless of treatment, showed an increase in Eif2 α P compared with their siblings, suggesting that a global reduction in translation arising from Eif2 α P contributed to the phenotypes observed.

To identify potential novel therapeutic agents for del(5q) MDS, we conducted an in vivo small-molecule screening for compounds that could alleviate anemia in Rps14-deficient embryos. The screening identified a striking rescue of the anemic phenotype with the TLR7/8 agonist imiquimod. Our data showed that imiquimod exerted its effect on erythroid cells via TLR7 signaling. We also showed a marked effect of imiquimod on *itga2b:GFP*-expressing HPSCs. Effects were observed in Rps14^{+/-} as well as Rps14^{+/+} embryos, but notably the effect in Rps14^{+/-} was more pronounced.

Proinflammatory signaling through TLR4 has been identified as a mechanism of anemia in Rps14-deficient mice, and blocking this signaling pathway can rescue this effect.¹¹ Rps14^{+/-} HSPCs showed upregulation of the TNF/NF- κ B signaling complex in our model, indicating conservation of this pathway. However, TLR7 ligation also activated this pathway through Myd88. Therefore, our findings that activation of this pathway alleviated anemia appeared counterintuitive. RNA sequencing data support that TLR7 activation in Rps14^{+/-} HSPCs paradoxically results in downregulation of inflammation, which we validated by measuring NF- κ B and IL1 β expression levels. A paradigm for such cross talk between activation of different TLRs and the effects of this on downstream signaling and homeostasis of inflammatory signaling has been elucidated for TLR3 and TLR7.⁴⁹ Coactivation of TLR3 and TLR7 leads to an enhanced production of some inflammatory cytokines; however, production of several key pathway intermediates, such as TRAF6, is reduced. Induction of inflammatory tolerance has also been described between TLR4 and TLR7/8 in monocytes, which requires microRNA 146a.⁵⁰ This suggests that, although some components of the innate immune response act in concert to enhance inflammatory signaling, there are underlying mechanisms in place to halt excessive immune activation, or even specifically reduce inflammation.

The effects of imiquimod in our model were not limited to increased HSPCs. Using the differentiation arrest observed in Gata1 morphants, we demonstrated an effect of imiquimod on erythroid (as well as myeloid) differentiation. Interestingly, Gata1 not only has a central role in the pathogenesis of ribosomal protein-mediated anemias, but is also thought to be key in cytopenias associated with activation of the inflammasome in general.

When comparing Rps14^{+/-}-stressed HSPCs with those of siblings, stressed HSPCs showed a significant increase in negative regulators of the canonical WNT pathway. Regulation of HSPC specification, emergence, expansion, and differentiation have all been shown

Figure 5. RNA sequencing analysis of HSPCs shows the effects on WNT and inflammatory signaling pathways. (A) Representative western blot of p-Eif2 α (phosphoserine 51) and Eif2 α total in Rps14 mutants at 6-dpf exposed to PHZ and/or imiquimod. (B) Normalized ratio (to untreated WT) of p-Eif2 α /total Eif2 α shown in 3 experiments, represented by different colored lines. The P-value refers to the effect of genotype on the ratio. (C) Differential gene expression of Rps14^{+/-} vs Rps14^{+/+} embryos shown as a volcano plot for all conditions combined. Rps14 is shown in bold. (D) Metascape Pathway Analysis of Rps14^{+/-} vs Rps14^{+/+} differentially expressed genes showing the top 20 enriched pathways. (E-F) GSEA analysis comparing Rps14^{+/-} with Rps14^{+/+} in DMSO-treated vs imiquimod-treated HSPCs. (E) Negative regulation of WNT signaling was enriched in Rps14^{+/-} vs Rps14^{+/+} DMSO-treated HSPCs, and the effect was reversed in imiquimod-treated HSPCs. (F) Similarly, inflammatory signaling was enriched in Rps14^{+/-} vs Rps14^{+/+} DMSO-treated HSPCs but suppressed in imiquimod-treated HSPCs. (G) Quantification of total fluorescence of NFKB/GFP at 4 dpf shows an increase with PHZ stress but a decrease with imiquimod in Rps14^{+/-} compared with Rps14^{+/+}. (H) PHZ causes an increase in *it1b* expression by in situ hybridization in Rps14^{+/-} which is rescued by imiquimod. Statistical comparisons are by 2-way ANOVA (B,H; genotype and condition) or ANOVA (G).




Figure 6. Imiquimod enhances erythroid output of human primary cells in vitro. (A-D) Primary cells obtained from BMs of anemic patients detailed in the supplemental Table 1 ($n = 4$) underwent fluorescence-activated cell sorting into different populations. Sort purity was verified as greater than 95% for all conditions. CFU-assays were performed in triplicate in Methocult without serum. Colonies were scored at 12 days, and output is shown as percentages of cells input. HSPCs (A), CMPs (B), MEPs (C), and granulocyte macrophage progenitors (GMPs) (D). (E-G) Individual patient plots show the change in colony output associated with imiquimod for MEPs (E-H) and CMPs (I-J). BFUE, burst-forming unit erythroid; GEMM, granulocyte, erythrocyte, macrophage, and megakaryocyte; GM/G, granulocyte-macrophage/granulocyte; M, macrophage; AML_PR, acute myeloid leukemia in partial remission; MDS-MD, myelodysplastic syndrome with multilineage dysplasia; DLBCL, diffuse large B-cell lymphoma.

to be tightly regulated, in part, by components of the WNT/ β -catenin pathway.^{51,52} However, temporally, both imiquimod treatment and the effects we observed occurred after specification and emergence of HSPCs, suggesting in this context that WNT pathway inhibition in stressed Rps14^{+/-} may impede expansion or differentiation of HSPCs and that this effect is alleviated by imiquimod. Furthermore, cross talk between NF- κ B inflammatory signaling and WNT pathway activation and/or inhibition has been reported in several cell types (reviewed in Ma and Hottiger⁵³), including evidence that prolonged TLR4-mediated inflammation suppresses WNT/ β -catenin in bone, resulting in apoptosis and necrosis.⁵⁴ Our study showed that possible cross talk may occur between these pathways.

Although, TLRs, their ligands, and the inflammatory consequences of signaling have been shown to differ among species,⁵⁵ TLR7 and TLR8 are the most highly conserved of all the TLRs, and inflammatory responses to R848 are preserved in fish.⁵⁶ Nonetheless, to establish the relevance of our findings in humans, we used BM cells from anemic patients to determine the effects of imiquimod. Our findings suggest that imiquimod can enhance erythroid output in anemic individuals at the level of both CMPs and MEPs, supporting the data from the fish. In these experiments, very few colonies were derived from HSCs of anemic patients; therefore, assessment of the effects of imiquimod on HSCs was not possible. One possibility is that the effects observed in our system are non-cell autonomous via other inflammatory cells. Most of functional effects of TLR7

signaling have been described via innate immune cells. Furthermore, we observed a larger inflammatory signaling response when analyzing downstream effector genes of TLR signaling in whole-embryo RNA extracts (Figure 5; supplemental Figure 7). Thus, the cell of origin of the effects observed in our study is not yet defined and is the focus of ongoing work.

Finally, a key unanswered question is how Rps14 deficiency and the associated effects on ribosome assembly and translation lead to activation of inflammatory signaling. Murine studies defined increased production of S100 proteins to be the mediators of increased inflammatory signaling via TLR4.¹¹ However, it is attractive to speculate that, given the structural knowledge that TLR7 activation by imiquimod is enhanced by single-stranded RNA species, the production of aberrant ribosomal RNA species observed in Rps14-knockout cells may contribute to our observation that the effects of imiquimod are more marked in Rps14-deficient cells.^{5,57} To date, no such phenomenon has been observed for endogenous RNA species outside of autoimmune disease.

In summary, we describe a model of del(5q) MDS in zebrafish and define a novel role for TLR7 in enhancing hematopoiesis in this model through modulation of the inflammatory response and differentiation.

Acknowledgments

The authors thank the CRUK-UCL flow cytometry core and UCL zebrafish facility for their assistance; and Catherine Loynes, Dave Drew, and Stephen Renshaw for facilitating the acquisition of new animal lines and reagents during the COVID lockdown period.

E.M.P. was supported by a CRUK Advanced Clinician Scientist Fellowship and is a former recipient of a Wellcome-Beit Intermediate Clinical Fellowship and the Leuka John Goldman

Fellowship for future science. C.H. was supported by a Medical Research Council Clinical Research Training Fellowship. O.P. was supported by BECAS Chile (CONICYT) and Overseas Research Scholarship (UCL). L.E.V. was supported by a FONDECYT grant (11160951) and Medical Research Council grants G0900994 and MR/L003775/1 (Steve W. Wilson and Gaia Gestri, Department of Cell and Developmental Biology, UCL). C.B. was supported by the Swedish Research Council (grant 2015-00135) and Marie Skłodowska Curie Actions, Cofund, and Project INCA (grant 600398).

Authorship

Contribution: E.M.P., O.A.P., and A.L. designed and performed the experiments; J.R., C.H., A.L., P.D., and Y.H. performed the experiments and contributed to scientific analysis and discussions; Y.J. conducted the screening with assistance from M.C.V. and O.A.P.; L.E.V. and K.T. made TALENS targeting *rps14*; and C.B. and S.R. provided essential technical assistance for human hematopoietic cell studies and analysis.

Conflict-of-interest disclosure: E.M.P. has received honoraria for consultancy for Novartis, Celgene, and Takeda that are not related to the work in this study. The remaining authors declare no competing financial interests.

ORCID profiles: O.A.P., 0000-0002-2582-0238; A.L., 0000-0001-6592-9513; J.R., 0000-0001-7040-8528; C.B., 0000-0002-4876-1218; M.C.V., 0000-0002-4940-188X; E.M.P., 0000-0001-5841-778X; S.R., 0000-0003-4343-4784.

Correspondence: Elspeth M. Payne, UCL Cancer Institute-314, 72 Huntley St, London WC1E6BT, United Kingdom; e-mail: e.payne@ucl.ac.uk.

References

1. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood*. 2007;110(13):4385-4395.
2. Hosono N, Makishima H, Mahfouz R, et al. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. *Oncotarget*. 2017;8(4):8632/ncotarget.14130.
3. Woll PS, Kjällquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo [published corrections appear in *Cancer Cell*. 2014;25(6):861 and 2015;27(4):603-605]. *Cancer Cell*. 2014;25(6):794-808.
4. Ban N, Beckmann R, Cate JHD, et al. A new system for naming ribosomal proteins. *Curr Opin Struct Biol*. 2014;24:165-169.
5. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. *Nature*. 2008;451(7176):335-339.
6. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haploinsufficiency in the selective suppression of deletion 5q MDS by lenalidomide [published correction appears in *Proc Natl Acad Sci USA*. 2013;110(35):14504]. *Proc Natl Acad Sci USA*. 2009;106(31):12974-12979.
7. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. *Nat Med*. 2010;16(1):49-58.
8. Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. *Cancer Cell*. 2014;26(4):509-520.
9. Varney ME, Niederkorn M, Konno H, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. *J Exp Med*. 2015;212(11):1967-1985.
10. Shan Y, Cortopassi G. Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-sulfur cluster assembly. *Mitochondrion*. 2016;26:94-103.
11. Schneider RK, Schenone M, Ferreira MV, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. *Nat Med*. 2016;22(3):288-297.

12. Payne EM, Virgilio M, Narla A, et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. *Blood*. 2012;120(11):2214-2224.
13. Espín-Palazón R, Stachura DL, Campbell CA, et al. Proinflammatory signaling regulates hematopoietic stem cell emergence. *Cell*. 2014;159(5):1070-1085.
14. Bugl S, Wirths S, Radsak MP, et al. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. *Blood*. 2013;121(5):723-733.
15. Li Y, Esain V, Teng L, et al. Inflammatory signaling regulates embryonic hematopoietic stem and progenitor cell production. *Genes Dev*. 2014;28(23):2597-2612.
16. Westerfield M. *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*. 5th edition. Eugene, OR: University of Oregon Press; 2007.
17. Feng Y, Renshaw S, Martin P. Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. *Curr Biol*. 2012;22(13):1253-1259.
18. Lin HF, Traver D, Zhu H, et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. *Blood*. 2005;106(12):3803-3810.
19. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. *Nat Immunol*. 2003;4(12):1238-1246.
20. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. *Dev Dyn*. 1995;203(3):253-310.
21. Reyon D, Maeder ML, Khayter C, et al. Engineering customized TALE nucleases (TALENs) and TALE transcription factors by fast ligation-based automatable solid-phase high-throughput (FLASH) assembly. *Curr Protoc Mol Biol*. 2013;chapter 12:unit 12.16.
22. Payne EM, Bolli N, Rhodes J, et al. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. *Blood*. 2011;118(4):903-915.
23. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. *Cell Host Microbe*. 2007;2(6):371-382.
24. Iuchi I, Yamamoto M. Erythropoiesis in the developing rainbow trout, *Salmo gairdneri* irideus: histochemical and immunochemical detection of erythropoietic organs. *J Exp Zool*. 1983;226(3):409-417.
25. Le Guyader D, Redd MJ, Colucci-Guyon E, et al. Origins and unconventional behavior of neutrophils in developing zebrafish. *Blood*. 2008;111(1):132-141.
26. Shafizadeh E, Peterson RT, Lin S. Induction of reversible hemolytic anemia in living zebrafish using a novel small molecule. *Comp Biochem Physiol C Toxicol Pharmacol*. 2004;138(3):245-249.
27. Duprey SP, Boettiger D. Developmental regulation of c-myc in normal myeloid progenitor cells. *Proc Natl Acad Sci USA*. 1985;82(20):6937-6941.
28. Balla KM, Lugo-Villarino G, Spitsbergen JM, et al. Eosinophils in the zebrafish: prospective isolation, characterization, and eosinophilia induction by helminth determinants. *Blood*. 2010;116(19):3944-3954.
29. Kulkeaw K, Ishitani T, Kanemaru T, Fucharoen S, Sugiyama D. Cold exposure down-regulates zebrafish hematopoiesis. *Biochem Biophys Res Commun*. 2010;394(4):859-864.
30. Lenard A, Alghisi E, Daff H, Donzelli M, McGinnis C, Lengerke C. Using zebrafish to model erythroid lineage toxicity and regeneration. *Haematologica*. 2016;101(5):e164-e167.
31. Zhang Z, Ohto U, Shibata T, et al. Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. *Immunity*. 2016;45(4):737-748.
32. Zhang Z, Ohto U, Shibata T, et al. Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. *Cell Rep*. 2018;25(12):3371-3381.e5.
33. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. *Science*. 2013;339(6126):1426-1429.
34. Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. *Nat Struct Mol Biol*. 2015;22(2):109-115.
35. Payne E, Sun H, Paw BH. Both p53-dependent and -independent pathways contribute to erythroid dysplasia in a zebrafish model for Diamond Blackfan anemia [abstract]. *Blood*. 2009;114(22). Abstract 177.
36. Blighe KRS, Lewis M. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. R package version, 1.6.0. 2020.
37. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun*. 2019;10(1):1523.
38. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005;102(43):15545-15550.
39. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*. 2003;34(3):267-273.
40. Rhodes J, Hagen A, Hsu K, et al. Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. *Dev Cell*. 2005;8(1):97-108.

41. Bibikova E, Youn M-Y, Danilova N, et al. TNF-mediated inflammation represses GATA1 and activates p38 MAP kinase in RPS19-deficient hematopoietic progenitors. *Blood*. 2014;124(25):3791-3798.
42. Doty RT, Yan X, Lausted C, et al. Single-cell analyses demonstrate that a heme-GATA1 feedback loop regulates red cell differentiation. *Blood*. 2019;133(5):457-469.
43. Gilles L, Arslan AD, Marinaccio C, et al. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. *J Clin Invest*. 2017;127(4):1316-1320.
44. Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. *Nat Med*. 2014;20(7):748-753.
45. Tyrkalska SD, Pérez-Oliva AB, Rodríguez-Ruiz L, et al. Inflammasome Regulates Hematopoiesis through Cleavage of the Master Erythroid Transcription Factor GATA1. *Immunity*. 2019;51(1):50-63.e5.
46. Boussaid I, Le Goff S, Floquet C, et al. Integrated analyses of transcriptome and proteome identify the rules of translation selectivity in RPS14-deficient cells. *Haematologica*. 2020;106(3):746-758.
47. Basiorka AA, McGraw KL, Eksioglu EA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. *Blood*. 2016;128(25):2960-2975.
48. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. *Blood*. 2019;133(10):1039-1048.
49. Liu B, Liu Q, Yang L, et al. Innate immune memory and homeostasis may be conferred through crosstalk between the TLR3 and TLR7 pathways. *Sci Signal*. 2016;9(436):ra70.
50. Nahid MA, Benso LM, Shin JD, Mehmet H, Hicks A, Ramadas RA. TLR4, TLR7/8 agonist-induced miR-146a promotes macrophage tolerance to MyD88-dependent TLR agonists. *J Leukoc Biol*. 2016;100(2):339-349.
51. Richter J, Traver D, Willert K. The role of Wnt signaling in hematopoietic stem cell development. *Crit Rev Biochem Mol Biol*. 2017;52(4):414-424.
52. Famili F, Brugman MH, Taskesen E, Naber BEA, Fodde R, Staal FJT. High levels of canonical wnt signaling lead to loss of stemness and increased differentiation in hematopoietic stem cells. *Stem Cell Reports*. 2016;6(5):652-659.
53. Ma B, Hottiger MO. Crosstalk between Wnt/ β -Catenin and NF- κ B Signaling Pathway during Inflammation. *Front Immunol*. 2016;7:378.
54. Pei J, Fan L, Nan K, et al. Excessive Activation of TLR4/NF- κ B Interactively Suppresses the Canonical Wnt/ β -catenin Pathway and Induces SANFH in SD Rats. *Sci Rep*. 2017;7(1):11928.
55. Yeh D-W, Liu Y-L, Lo Y-C, et al. Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish. *Proc Natl Acad Sci USA*. 2013;110(51):20711-20716.
56. Pietretti D, Wiegertjes GF. Ligand specificities of Toll-like receptors in fish: indications from infection studies. *Dev Comp Immunol*. 2014;43(2):205-222.
57. Hellmich UA, Weis BL, Lioutikov A, et al. Essential ribosome assembly factor Fap7 regulates a hierarchy of RNA-protein interactions during small ribosomal subunit biogenesis. *Proc Natl Acad Sci USA*. 2013;110(38):15253-15258.
58. Dobrzycki T, Krecsmarik M, Bonkhofer F, Patient R, Monteiro R. An optimised pipeline for parallel image-based quantification of gene expression and genotyping after *in situ* hybridisation. *Biol Open*. 2018;7(4):bio031096.